Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (531-540 of 1,137) with videos related to

Pageof 114
Sort By:
American Heart Journal|April 29, 2008
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useMarc S Sabatine, Hussam N Hamdalla, Shamir R Mehta, et al.
International Journal of Cardiology|January 12, 2008
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromesShaheeda Ahmed, Christopher P Cannon, Robert P Giugliano, et al.
International Journal of Cardiology|December 19, 2024
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registryBenjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, et al.
Journal of the American College of Cardiology|November 25, 2000
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudyD A Morrow, E M Antman, M Tanasijevic, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Clinical Chemistry|July 26, 2003
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromesDavid A Morrow, Nader Rifai, Marc S Sabatine, et al.
Critical Pathways in Cardiology|March 11, 2010
Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease programWarren Laskey, Nathan Spence, Xin Zhao, et al.
American Heart Journal|October 18, 2008
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular diseaseBenjamin A Steinberg, Deepak L Bhatt, Shamir Mehta, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Kidney International Reports|August 15, 2022
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV TrialDavid Z I Cherney, Samuel Dagogo-Jack, Francesco Cosentino, et al.
Pageof 114

Showing results (531-540 of 1,137) with videos related to

Sort By:
Pageof 114
American Heart Journal|April 29, 2008
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useMarc S Sabatine, Hussam N Hamdalla, Shamir R Mehta, et al.
International Journal of Cardiology|January 12, 2008
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromesShaheeda Ahmed, Christopher P Cannon, Robert P Giugliano, et al.
International Journal of Cardiology|December 19, 2024
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registryBenjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, et al.
Journal of the American College of Cardiology|November 25, 2000
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudyD A Morrow, E M Antman, M Tanasijevic, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Clinical Chemistry|July 26, 2003
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromesDavid A Morrow, Nader Rifai, Marc S Sabatine, et al.
Critical Pathways in Cardiology|March 11, 2010
Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease programWarren Laskey, Nathan Spence, Xin Zhao, et al.
American Heart Journal|October 18, 2008
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular diseaseBenjamin A Steinberg, Deepak L Bhatt, Shamir Mehta, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Kidney International Reports|August 15, 2022
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV TrialDavid Z I Cherney, Samuel Dagogo-Jack, Francesco Cosentino, et al.
Pageof 114